Neyssa Marina

Clinical Trials

• Not Recruiting MLN8237 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
• Not Recruiting Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
• Recruiting Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
• Not Recruiting Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
• Not Recruiting Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
• Recruiting Enrollment on the Childhood Cancer Research Network (CCRN) of the Children's Oncology Group
• Recruiting Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
• Not Recruiting Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes
• Not Recruiting EZN-2285 or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
• Not Recruiting Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
• Not Recruiting Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms Tumor
• Recruiting Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
• Recruiting Study of Blood Samples From Newborns With Down Syndrome
• Recruiting Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
• Recruiting Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia
• Recruiting Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
• Recruiting Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia
• Recruiting Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
• Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
• Recruiting Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
• Recruiting Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
• Recruiting Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor
• Recruiting Study of Late-Occurring Complications in Childhood Cancer Survivors
• Recruiting Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma
• Recruiting Study of Kidney Tumors in Young Patients
• Recruiting Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor
• Recruiting Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
• Recruiting Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor
• Recruiting Genomic Analysis of Pediatric Bone Tumors
• Recruiting Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
• Not Recruiting Treatment of Blood Clots in Children With Cancer
• Not Recruiting Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma
• Recruiting Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
• Recruiting Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
• Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
• Recruiting Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
• Recruiting Collecting and Storing Biological Samples From Patients With Ewing Sarcoma
• Recruiting Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma
• Recruiting Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)
• Recruiting Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
• Recruiting Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
• Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer
• Recruiting Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
• Recruiting Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
• Recruiting Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
• Recruiting Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
• Recruiting Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms Tumor
• Recruiting Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
• Recruiting Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
• Recruiting Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma
• Not Recruiting Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma
• Not Recruiting Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
• Not Recruiting Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma
• Not Recruiting Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors
• Not Recruiting Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors
• Not Recruiting Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
• Not Recruiting Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma
• Not Recruiting A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.
• Not Recruiting Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma
• Not Recruiting Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging
• Not Recruiting Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
• Not Recruiting Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
• Not Recruiting Erwinase Master Treatment Protocol
• Not Recruiting Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
• Not Recruiting Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia
• Not Recruiting cRisk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
• Not Recruiting Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
• Not Recruiting Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
• Not Recruiting Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
• Not Recruiting Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
• Not Recruiting Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
• Not Recruiting Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma
• Not Recruiting Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
• Not Recruiting Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
• Not Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
• Not Recruiting Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer
• Not Recruiting Long-Term Effects of Treatment in Patients Previously Treated for Childhood Hodgkin's Lymphoma
• Not Recruiting Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
• Not Recruiting Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
• Not Recruiting Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
• Not Recruiting Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors
• Not Recruiting hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma
• Not Recruiting Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer
• Not Recruiting Combination Chemotherapy in Treating Children or Adolescents With Newly Diagnosed Stage III or Stage IV Lymphoblastic Lymphoma
• Not Recruiting Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma
• Not Recruiting High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma
• Not Recruiting Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
• Not Recruiting Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
• Not Recruiting Vincristine, Topotecan, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma
• Not Recruiting A Study of Pemetrexed in Children With Recurrent Cancer
• Not Recruiting ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
• Not Recruiting Ixabepilone in Treating Young Patients With Refractory Solid Tumors
• Not Recruiting A Study of R1507 in Patients With Recurrent or Refractory Sarcoma.
• Not Recruiting Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
• Not Recruiting Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors
• Not Recruiting Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
• Not Recruiting Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma
• Not Recruiting Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
• Not Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
• Not Recruiting Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma
• Not Recruiting Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
• Not Recruiting Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
• Not Recruiting Epratuzumab and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia
• Not Recruiting Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary CNS Germ Cell Tumor
• Recruiting Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma
• Recruiting Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
• Not Recruiting Sorafenib (BAY 43-9006) to Treat Children With Solid Tumors or Leukemias
• Not Recruiting Ecteinascidin 743 in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
• Not Recruiting Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
• Not Recruiting Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
• Not Recruiting Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes
• Not Recruiting Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
• Not Recruiting Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma
• Not Recruiting Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
• Recruiting A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
• Recruiting Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy For Favorable Risk Pediatric Hodgkin Lymphoma
• Recruiting Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma